Why the study?
The study was conducted to evaluate the safety and efficacy of DOACs compared with conventional oral antithrombotics in patients with diabetes mellitus and coexisting AF risk, particularly concerning interactions with anti-glycemic agents.
Do direct oral anticoagulants (DOACs) improve safety and efficacy compared to conventional oral antithrombotics in diabetic patients with atrial fibrillation?
Do direct oral anticoagulants (DOACs) improve safety and efficacy compared to conventional oral antithrombotics in diabetic patients with atrial fibrillation?
DOACs may offer a safer alternative to conventional oral antithrombotics in patients with diabetes and atrial fibrillation by reducing the risks of hypoglycemia and bleeding.
DOACs were associated with lower hypoglycemia and bleeding risks in this cross-sectional diabetic AF analysis; prospective RCTs are needed to confirm.
The prevalence of diabetes mellitus (DM) is rapidly improving and leads to metabolic disease and severe complications. This study assessed the safety and efficacy of antithrombotics in patients with diabetes, and their complications and coexisting atrial fibrillation (AF) risk. It compared the effectiveness and safety of direct oral anticoagulants (DOACs) to conventional oral antithrombotic (OAT) medications (warfarin and aspirin) concerning anti-glycemic agents. This is a cross-sectional study. Primary data was collected through a questionnaire when interviewing the patients, followed by a systemic review using clinical scores such as the congestive heart failure, hypertension, age, diabetes mellitus, prior stroke or transient ischaemic attack (TIA) or thromboembolism, vascular disease, age, sex category (CHA2DS2-VASc), and Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International normalized ratio (INR), Elderly, Drugs/Alcohol Concomitantly (HAS-BLED). Secondary data collection involved a thorough review of existing research and literature. Significant interactions were observed between antithrombotic and anti-glycemic agents. Warfarin combined with sulfonylurea or metformin posed moderate to severe hypoglycemic risks. Insulin has a weak interaction with warfarin, reflecting a low hypoglycemia risk. Aspirin showed a moderate risk only with sulfonylurea. Warfarin and aspirin are associated with a higher risk of bleeding with sulfonylurea, but a minimal risk with metformin and insulin. OATs have a 60.8% risk of hypoglycemia and a 55.1% risk of bleeding. DOAC showed strong correlations in reducing stroke and hypoglycemia (Pearson correlation coefficient [PCC] is 0.969), and a strong correlation in reducing bleeding (PCC is 0.769). These findings suggest that DOACs may offer a safer alternative to OATs in patients with diabetes and AF.
No takes yet. Share an insight, caveat, or question.
Amer et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: